Dr. Mike Stebbins

Dr. Stebbins is Senior Vice President of ATI and oversees the Medical & Threat Countermeasures Division. This Division includes six unique Other Transaction (OT) Agreement programs for HHS and DoD valued at greater than $50B. The HHS portfolio includes BARDA’s Rapid Response Partnership Vehicle (RRPV) and BARDA’s Biopharmaceutical Manufacturing Preparedness – Consortium (BioMaP), as well as ARPA-H’s Customer Experience Hub, part of the ARPANET-H Network. On the DoD side the portfolio includes the Medical Technology Enterprise Consortium (MTEC), the Medical CBRN Defense Consortium (MCDC)) and the Countering Weapons of Mass Destruction Consortium (CWMD).

Mike led the startup of two biotech/health related OT efforts and since inception has led the execution of over $10B of funded prototype development projects through the MCDC and CWMD consortia. He also serves as the Executive Director for both the MCDC and CWMD Consortia, as in his role as the Program Executive for RRPV, Bio-MaP and Customer Experience Hub is guiding the startup of these important new initiatives.

Mike also played a key role in winning and then executing the UI LABS-led Digital Manufacturing and Design Innovation Institute (DMDII, now MxD), one of several Manufacturing Innovation Institutes. Other projects include an effort at Ft. Sumter National Monument to incorporate solar panel technology with hydrogen fuel cells to create an energy production and backup power system and an effort to incorporate landfill gas converted to hydrogen as a fuel to power material handling equipment at BMW’s South Carolina production facility. Finally, Mike was a key participant in ATI’s Copper Touch Surfaces and Copper Air Quality programs -- designed to demonstrate and validate that the introduction of copper reduces levels of harmful microbes.
Mike was awarded a Ph.D. in analytical chemistry from the University of Tennessee, Knoxville and a B.S. in chemistry from the College of Charleston.